TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01535053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV and IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00179634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visualization relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Milieu Enhancement (Fine art photograph)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Milieu Enhancement (Fine art photograph)
Study: NCT02893878

Intervention type: OTHER
Intervention: Vaccine safety surveillance
Description: Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.

Intervention type: OTHER
Intervention: Vaccine safety surveillance
Description: Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.

Intervention type: OTHER
Intervention: Vaccine safety surveillance
Description: Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
Study: NCT01892228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate post-screening treatment education
Description: immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
Study: NCT01386554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: Acthar given SC for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: Acthar given SC for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week).
Study: NCT02499302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental training
Study: NCT03542981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Interferential Current
Study: NCT04541940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Therapy
Description: Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Rehabilitation Therapy
Description: Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
Study: NCT01463540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A 20 Fr gastrostomy tube, placed using push/pull techniques.
Description: In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A 20 Fr balloon type tube, placed after gastropexy.
Description: In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
Study: NCT01385202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH™ Catheter
Description: AF Ablation
Study: NCT03092154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents (Artovastatin)
Description: Artovastatin 20 mg /day, orally, 12 consecutive weeks.
Study: NCT02106091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM11
Description: Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
Study: NCT03959358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
Study: NCT06422130

Intervention type: OTHER
Intervention: Pregnant women and their offspring without intervention
Description: Pregnant women and their offspring with those exposures of interest determined in specific research based on the database
Study: NCT02940977

Intervention type: OTHER
Intervention: Blood draws
Description: Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
Study: NCT01359397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab
Description: Her2 - patients only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
Description: for Her2 + patients only
Study: NCT03187197

Intervention type: DRUG
Intervention: Pradaxa®
Description: Dabigatran etexilate

Intervention type: DRUG
Intervention: Pradaxa®
Description: Dabigatran etexilate
Study: NCT02961075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local surface anesthesia
Description: Airway anesthesia for Bronchoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local surface anesthesia
Description: Airway anesthesia for Bronchoscopy
Study: NCT04238598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse Radiofrequency
Description: Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Intra- Articular Injection
Description: Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Intra-Articular Injection
Description: Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
Study: NCT02961075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Study: NCT03090711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
Study: NCT02750345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered.
Study: NCT03520114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RP sling placement
Description: A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
Study: NCT03846726

Intervention type: PROCEDURE
Intervention: standard TME surgery
Description: radical resection for rectal cancer
Study: NCT00608023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tesamorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tesamorelin
Study: NCT01681069

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-VV-102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03967028

Intervention type: PROCEDURE
Intervention: cesarean section
Description: lower segment cesarean section either elective or emergency
Study: NCT00730041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pillar Palatal Implant System
Description: The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
Study: NCT03520114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIS placement
Description: The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally. The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of Sodium Chloride (NaCl). Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
Study: NCT03755102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily
Study: NCT04441606

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04 PET/CT
Description: * Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~* Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~* Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression.
Study: NCT01511315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
Study: NCT00674544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
Study: NCT00869154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: primary care follow up
Description: Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary follow up
Description: Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
Study: NCT06058481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blockbuster
Description: The investigator inserted the BlockBuster in Group A patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal-LMA
Description: The investigator inserted the Proseal-LMA in Group B patients.
Study: NCT04186039

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging - Blood Oxygenation Level Dependent
Description: First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence.
Study: NCT01799538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol inhaler
Description: 2 puffs of Metered Dose inhaler for Bronchodilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol nebulizer
Description: Albuterol administered by nebulization will produce a greater increase in FEV1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFT
Description: Breathing Test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PFT
Description: Breathing Test
Study: NCT00730041

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham system
Description: The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
Study: NCT02180919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE marked Philips Motiva system
Description: Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
Study: NCT03966963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization Reprocessing (EMDR)
Description: Trauma-Focused Therapy
Study: NCT01273116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CWS in Hospital
Description: Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients.
Study: NCT04083508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mosquito bites
Description: Successful feeding of 5 infected P. vivax mosquitoes
Study: NCT01801436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
Study: NCT00246051

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene Education
Description: An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.

Intervention type: OTHER
Group type: OTHER
Intervention: Expert-Led Sleep Disorders Screening and Treatment
Description: Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician

Intervention type: OTHER
Group type: OTHER
Intervention: Online Sleep Disorders Screening
Description: Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.